ArticleFood chemistry: X2023
Preparation and in vitro evaluation of hesperidin nanoparticles by antisolvent recrystallization in a double homogenate system.
Article in Food chemistry: X, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Hesperidin: a bioflavonoid with broad therapeutic promise.Inflammopharmacology · 2026Review
- Development of hesperidin loaded lipid-chitosan nanoparticles: physicochemical characterization, molecular docking and ex vivo study.Scientific reports · 2026Article
- Impact of two different hesperidin forms loaded on nanoscale modified borate bioglass scaffolds on rat critical-sized calvarial defects.Scientific reports · 2026Article
- Solid Dispersion of Hesperidin Alleviates Acetic Acid-Induced Colitis Through Modulating the Gut Microbiota Dysbiosis in Rats.Foods (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hesperidin nanoparticles (HNPs) were made for the first time employing an antisolvent recrystallization technique in a double homogenate system with positive and negative clockwise rotation in order to completely use the underutilized nutritional components in citrus peel. Dimethyl sulfoxide (DMSO), ethanol, and deionized water were used as the solvents and antisolvents in the hesperidin solution preparation. Hesperidin solution concentration of 60.26 mg/mL, homogenization speed of 8257 rpm, antisolvent-to-solvent volume ratio of 6.93 mL/mL, and homogenization time of 3.15 min were the ideal experimental conditions. HNPs have to be at least 72.24 nm in size. The structures of the produced hesperidin samples and the raw hesperidin powder were identical, according to the findings of the FTIR, XRD, and TG characterization tests. The HNP sample had an in vitro absorption rate that was 5.63 and 4.23 times greater than that of the raw hesperidin powder, respectively. It was discovered that DMSO was more suited than ethanol for creating HNP particles. In the realms of dietary supplements, therapeutic applications, and health promotion, the HNPs produced by the ARDH technology would be a potential formulation on increasing uses for a wider range of nutraceuticals (synergistic).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.